{"id":48625,"date":"2025-11-19T14:29:17","date_gmt":"2025-11-19T06:29:17","guid":{"rendered":"https:\/\/flcube.com\/?p=48625"},"modified":"2025-11-19T14:29:19","modified_gmt":"2025-11-19T06:29:19","slug":"roches-giredestrant-serd-achieves-idfs-win-in-phase-3-lidera-breast-cancer-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48625","title":{"rendered":"Roche&#8217;s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial"},"content":{"rendered":"\n<p><strong>Roche<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX: ROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced its investigational oral SERD <strong>giredestrant<\/strong> met the primary endpoint at a pre\u2011specified interim analysis in the <strong>Phase\u202fIII lidERA study<\/strong>, demonstrating a statistically significant and clinically meaningful improvement in invasive disease\u2011free survival (iDFS) vs standard endocrine therapy in patients with ER+\/HER2\u2011 early breast cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-milestone\">Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>giredestrant<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Roche<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>lidERA Phase\u202fIII<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adjuvant ER+, HER2\u2011 early breast cancer<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Invasive disease\u2011free survival (iDFS)<\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td>Statistically significant and clinically meaningful improvement vs standard endocrine therapy<\/td><\/tr><tr><td><strong>Analysis<\/strong><\/td><td>Pre\u2011specified interim analysis<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Regulatory submissions to FDA and EMA anticipated H2\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Oral, potent, next\u2011generation <strong>Selective Estrogen Receptor Degrader (SERD)<\/strong> and complete antagonist<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks estrogen binding to the estrogen receptor and triggers receptor degradation, halting cancer cell growth<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Oral convenience vs. injectable fulvestrant; next\u2011gen profile may offer efficacy\/safety advantages over current standards (tamoxifen, aromatase inhibitors)<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Extensive clinical development program with <strong>five company\u2011sponsored Phase\u202fIII trials<\/strong> across various treatment stages and lines of therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-summary\">Clinical Evidence Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result vs Standard Endocrine Therapy<\/th><\/tr><\/thead><tbody><tr><td><strong>iDFS<\/strong><\/td><td>Statistically significant and clinically meaningful improvement (hazard ratio and confidence intervals to be presented at upcoming medical conference)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> Global adjuvant endocrine therapy market for ER+\/HER2\u2011 early breast cancer projected at <strong>$8\u201110\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project peak global sales potential for giredestrant in this indication at <strong>$1.5\u20112.0\u202fbillion<\/strong> if approved, assuming 20\u201125% market share capture<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Oral SERD class has faced setbacks (e.g., Sanofi\u2019s amcenestrant); successful candidates like <strong>AstraZeneca\u2019s camizestrant<\/strong> and <strong>Eli Lilly\u2019s imlunestrant<\/strong> remain in development. Giredestrant\u2019s positive iDFS data positions it as a potential leader in the next\u2011wave oral SERDs<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Positive adjuvant data could support broader label expansion across metastatic and earlier\u2011stage settings, bolstering Roche\u2019s oncology portfolio amid biosimilar pressure on legacy products<\/li>\n\n\n\n<li><strong>Regulatory Edge:<\/strong> Interim iDFS success may enable accelerated approval pathways, shortening time\u2011to\u2011market by 12\u201118 months vs. traditional full\u2011trial readouts<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding giredestrant\u2019s clinical development, regulatory submissions, and commercial potential. Actual results may differ materially due to risks including final trial data, regulatory review outcomes, and competitive dynamics in the endocrine therapy market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,17,940,163,939],"class_list":["post-48625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-results","tag-otcmkts-rhhby","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche&#039;s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint at a pre\u2011specified interim analysis in the Phase\u202fIII lidERA study, demonstrating a statistically significant and clinically meaningful improvement in invasive disease\u2011free survival (iDFS) vs standard endocrine therapy in patients with ER+\/HER2\u2011 early breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48625\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial\" \/>\n<meta property=\"og:description\" content=\"Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint at a pre\u2011specified interim analysis in the Phase\u202fIII lidERA study, demonstrating a statistically significant and clinically meaningful improvement in invasive disease\u2011free survival (iDFS) vs standard endocrine therapy in patients with ER+\/HER2\u2011 early breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48625\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T06:29:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-19T06:29:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche&#8217;s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial\",\"datePublished\":\"2025-11-19T06:29:17+00:00\",\"dateModified\":\"2025-11-19T06:29:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625\"},\"wordCount\":397,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901.webp\",\"keywords\":[\"Cancer\",\"Clinical trial results\",\"OTCMKTS: RHHBY\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48625#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48625\",\"name\":\"Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901.webp\",\"datePublished\":\"2025-11-19T06:29:17+00:00\",\"dateModified\":\"2025-11-19T06:29:19+00:00\",\"description\":\"Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint at a pre\u2011specified interim analysis in the Phase\u202fIII lidERA study, demonstrating a statistically significant and clinically meaningful improvement in invasive disease\u2011free survival (iDFS) vs standard endocrine therapy in patients with ER+\\\/HER2\u2011 early breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48625\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48625#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche&#8217;s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint at a pre\u2011specified interim analysis in the Phase\u202fIII lidERA study, demonstrating a statistically significant and clinically meaningful improvement in invasive disease\u2011free survival (iDFS) vs standard endocrine therapy in patients with ER+\/HER2\u2011 early breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48625","og_locale":"en_US","og_type":"article","og_title":"Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial","og_description":"Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint at a pre\u2011specified interim analysis in the Phase\u202fIII lidERA study, demonstrating a statistically significant and clinically meaningful improvement in invasive disease\u2011free survival (iDFS) vs standard endocrine therapy in patients with ER+\/HER2\u2011 early breast cancer.","og_url":"https:\/\/flcube.com\/?p=48625","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-19T06:29:17+00:00","article_modified_time":"2025-11-19T06:29:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48625#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48625"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche&#8217;s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial","datePublished":"2025-11-19T06:29:17+00:00","dateModified":"2025-11-19T06:29:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48625"},"wordCount":397,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48625#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901.webp","keywords":["Cancer","Clinical trial results","OTCMKTS: RHHBY","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48625#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48625","url":"https:\/\/flcube.com\/?p=48625","name":"Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48625#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48625#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901.webp","datePublished":"2025-11-19T06:29:17+00:00","dateModified":"2025-11-19T06:29:19+00:00","description":"Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint at a pre\u2011specified interim analysis in the Phase\u202fIII lidERA study, demonstrating a statistically significant and clinically meaningful improvement in invasive disease\u2011free survival (iDFS) vs standard endocrine therapy in patients with ER+\/HER2\u2011 early breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48625#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48625"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48625#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901.webp","width":1080,"height":608,"caption":"Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48625#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche&#8217;s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48625"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48625\/revisions"}],"predecessor-version":[{"id":48628,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48625\/revisions\/48628"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48627"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}